Literature DB >> 12011067

Mediation of the DCC apoptotic signal by DIP13 alpha.

Jiayou Liu1, Fayi Yao, Ruping Wu, Michael Morgan, Andrew Thorburn, Russell L Finley, Yong Q Chen.   

Abstract

DCC (deleted in colorectal cancer) is a candidate tumor suppressor gene. However the function of DCC remains elusive. Previously, we demonstrated that forced expression of DCC induces apoptosis or cell cycle arrest (Chen, Y. Q., Hsieh, J. T., Yao, F., Fang, B., Pong, R. C., Cipriano, S. C. & Krepulat, F. (1999) Oncogene 18, 2747-2754). To delineate the DCC-induced apoptotic pathway, we have identified a protein, DIP13 alpha, which interacts with DCC. The DIP13 alpha protein has a pleckstrin homology domain and a phosphotyrosine binding domain. It interacts with a region on the DCC cytoplasmic domain that is required for the induction of apoptosis. Although ectopic expression of DIP13 alpha alone causes only a slight increase in apoptosis, co-expression of DCC and DIP13 alpha results in an approximately 5-fold increase in apoptosis. Removal of the DCC-interacting domain on DIP13 alpha abolishes its ability to enhance DCC-induced apoptosis. Inhibition of endogenous DIP13 alpha expression by small interfering RNA blocks DCC-induced apoptosis. Our data suggest that DIP13 alpha is a mediator of the DCC apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011067     DOI: 10.1074/jbc.M204679200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  Dependence receptors: between life and death.

Authors:  P Mehlen; C Thibert
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

2.  GIPC is recruited by APPL to peripheral TrkA endosomes and regulates TrkA trafficking and signaling.

Authors:  Tal Varsano; Meng-Qiu Dong; Ingrid Niesman; Hyacynth Gacula; Xiaojing Lou; Tianlin Ma; Joseph R Testa; John R Yates; Marilyn G Farquhar
Journal:  Mol Cell Biol       Date:  2006-10-02       Impact factor: 4.272

3.  APPL1, APPL2, Akt2 and FOXO1a interact with FSHR in a potential signaling complex.

Authors:  Cheryl A Nechamen; Richard M Thomas; James A Dias
Journal:  Mol Cell Endocrinol       Date:  2006-10-09       Impact factor: 4.102

4.  Dependence receptors: mechanisms of an announced death.

Authors:  Chantal Thibert; Joanna Fombonne
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

5.  A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway.

Authors:  Kai S Erdmann; Yuxin Mao; Heather J McCrea; Roberto Zoncu; Sangyoon Lee; Summer Paradise; Jan Modregger; Daniel Biemesderfer; Derek Toomre; Pietro De Camilli
Journal:  Dev Cell       Date:  2007-09       Impact factor: 12.270

Review 6.  APPL1: role in adiponectin signaling and beyond.

Authors:  Sathyaseelan S Deepa; Lily Q Dong
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-14       Impact factor: 4.310

7.  Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.

Authors:  Liu Meimei; Li Peiling; Li Baoxin; Li Changmin; Zhuang Rujin; Hu Chunjie
Journal:  Med Oncol       Date:  2010-01-07       Impact factor: 3.064

8.  Cdo interacts with APPL1 and activates Akt in myoblast differentiation.

Authors:  Gyu-Un Bae; Jae-Rin Lee; Bok-Geon Kim; Ji-Won Han; Young-Eun Leem; Hey-Jin Lee; Seok-Man Ho; Myong-Joon Hahn; Jong-Sun Kang
Journal:  Mol Biol Cell       Date:  2010-05-19       Impact factor: 4.138

9.  Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription.

Authors:  Sajid Rashid; Iwona Pilecka; Anna Torun; Marta Olchowik; Beata Bielinska; Marta Miaczynska
Journal:  J Biol Chem       Date:  2009-05-11       Impact factor: 5.157

10.  Functional characterization of the interactions between endosomal adaptor protein APPL1 and the NuRD co-repressor complex.

Authors:  Magdalena Banach-Orlowska; Iwona Pilecka; Anna Torun; Beata Pyrzynska; Marta Miaczynska
Journal:  Biochem J       Date:  2009-10-12       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.